Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.

Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ

The lancet. Diabetes & endocrinology17 Sept 2019Cited by 233 (Europe PMC)

PMID31540867DOI10.1016/s2213-8587(19)30311-0PepBankPUB-31540867

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, once-weekly semaglutide 1.0 mg reduced HbA1c more than daily canagliflozin 300 mg at week 52.
In plain wordsIn adults with type 2 diabetes on metformin, weekly semaglutide lowered HbA1c more than canagliflozin after 52 weeks.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at week 52
Study
n = 788
Comparator
Canagliflozin 300 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−0.49 percentage points
week 52
Source sentences
Summary
patients receiving semaglutide had significantly greater reductions in HbA_1c and bodyweight than those receiving canagliflozin (HbA_1c estimated treatment difference [ETD] -0·49 percentage points, 95% CI -0·65 to -0·33; -5·34 mmol/mol, 95% CI -7·10 to -3·57; p<0·0001; and bodywe…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries.
Summary · context
Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily.
Report a problemFND-3154086701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, once-weekly semaglutide 1.0 mg reduced bodyweight more than daily canagliflozin 300 mg at week 52.
In plain wordsIn adults with type 2 diabetes on metformin, weekly semaglutide led to more weight loss than canagliflozin after 52 weeks.
Peptide
Semaglutide
Outcome
DecreaseBodyweight change at week 52
Study
n = 788
Comparator
Canagliflozin 300 mg
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−1.06 kg
week 52
Source sentences
Summary
patients receiving semaglutide had significantly greater reductions in HbA_1c and bodyweight than those receiving canagliflozin (HbA_1c estimated treatment difference [ETD] -0·49 percentage points, 95% CI -0·65 to -0·33; -5·34 mmol/mol, 95% CI -7·10 to -3·57; p<0·0001; and bodywe…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries.
Summary · context
Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily.
Report a problemFND-3154086702
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, gastrointestinal disorders, most commonly nausea, were the most frequent adverse events with semaglutide, in 184 of 392 patients.
In plain wordsIn adults with type 2 diabetes, 47% on weekly semaglutide had stomach or gut side effects, most often nausea.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n = 392
Comparator
Canagliflozin 300 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Gastrointestinal disorders
47%
semaglutide
Source sentences
Summary
Gastrointestinal disorders, most commonly nausea, were the most frequently reported adverse events with semaglutide, occurring in 184 (47%) of 392 patients
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries.
Summary · context
Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily.
Report a problemFND-3154086703
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, discontinuation because of adverse events occurred in 10% with semaglutide and 5% with canagliflozin.
In plain wordsIn adults with type 2 diabetes, 10% stopped weekly semaglutide because of side effects, compared with 5% on canagliflozin.
Peptide
Semaglutide
Outcome
IncreaseDiscontinuation because of adverse events
Study
n = 392
Comparator
Canagliflozin 300 mg
Outcome group
Adverse events · Whole body
Studied dose
1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Discontinuation due to AEs
10%
semaglutide
Discontinuation due to AEs
5%
canagliflozin
Source sentences
Summary
Premature treatment discontinuation because of adverse events occurred in 38 (10%) of 392 patients with semaglutide and in 20 (5%) of 394 patients with canagliflozin.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries.
Summary · context
Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily.
Report a problemFND-3154086704
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, one fatal adverse event in the semaglutide group was confirmed unlikely to be caused by treatment.
In plain wordsIn adults with type 2 diabetes, one death occurred in the semaglutide group and was judged unlikely to be caused by treatment.
Peptide
Semaglutide
Outcome
Not applicableFatal adverse event
Study
n = 392
Comparator
Canagliflozin 300 mg
Outcome group
Mortality · Whole body
Studied dose
1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
One fatal adverse event confirmed unlikely to be caused by treatment occurred in the semaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries.
Summary · context
Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily.
Report a problemFND-3154086705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03136484

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 78815 Mar 2017 to 16 Nov 2018

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 21 Jan 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.